精品自拍偷拍一区二区,亚洲国产精品一区二区高清无码久久,精品日产卡一卡二卡国色天香

伊沙妥昔單抗

NMR下載 COA and HPLC MSDS下載
names：
Isatuximab
CAS號(hào)：
1461640-62-9
MDL Number：
MF(分子式)： MW(分子量)：
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫存描述	數(shù)量	總計(jì) (￥)
DBK502210-500mg	500mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00
DBK502210-100mg	100mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00

大包裝詢價(jià) 提供各種包裝，敬請垂詢
收藏商品商品點(diǎn)評(píng) 加入購物車立即購買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	伊沙妥昔單抗
英文別名	Isatuximab
CAS號(hào)	1461640-62-9
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
溶解度Solubility
性狀	Solid
儲(chǔ)藏條件 Storage conditions

伊沙妥昔單抗使用注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害。
3.取樣品的移液槍頭需及時(shí)更換，必要時(shí)為避免交叉污染盡可能選擇濾芯吸頭。
4.稱量藥品時(shí)選用稱量紙，并無風(fēng)處取藥和稱量以免揚(yáng)撒，試劑的容器使用前務(wù)必確保干凈，并消毒。
5.取藥品時(shí)盡量采用多個(gè)藥勺分別使用，使用后清洗干凈。
6.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染。
大規(guī)格定制：定制產(chǎn)品請將信息發(fā)送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產(chǎn)品說明	Organic Acids
Introduction
Application1	Multiple myeloma is a blood cancer characterized by an overproduction of malignant plasma cells in the bone marrow. A unique characteristic of myeloma cells is their dense and uniform expression of CD38 surface glycoproteins - these proteins, also expressed in relatively minor quantities on other lymphoid and myeloid cells, have been identified as performing several critical cellular functions, and this, along with their relative abundance on myeloma cells, has made them an attractive target for multiple myeloma treatment. CD38 was first identified as an activation marker, but has subsequently demonstrated roles in adhesion to endothelial CD31 proteins, as an accessory component of the synapse complex, and as an ectoenzyme involved in the metabolism of extracellular NAD+ and cytoplasmic NADP. The products of CD38’s ectoenzymatic activity include the calcium-mobilizing compound adenosine diphosphate ribose (ADPR), which can be further metabolized by CD203a/PC-1 and CD73 to adenosine, an immunosuppressive molecule that may play a role in tumour cell evasion of the immune system.2Isatuximab is an IgG1-derived monoclonal antibody targeted against CD38 proteins.9Its activity against CD38 results in a number of downstream effects, including direct apoptosis of the affected cell and activation of immune mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC), all of which result in potent anti-tumour activity.9,2Via allosteric antagonism, isatuximab also inhibits CD38 ectoenzymatic activity, preventing the immunosuppressive effects of its downstream products.Isatuximab may also exert its effects via downstream promotion of lysosome-dependent cell death, upregulation of reactive oxygen species, and restoration of antitumor immune effector cell functions.2TargetActionsOrganismUADP-ribosyl cyclase 1inhibitorHumans
Application2
Application3

警示圖
危險(xiǎn)性
危險(xiǎn)性警示	warning
安全聲明
安全防護(hù)
備注	實(shí)驗(yàn)過程中防止吸入、食如，做好安全防護(hù)